Lyell Immunopharma/$LYEL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Ticker

$LYEL
Sector
Health
Primary listing
NASDAQ

Employees

300
Headquarters
South San Francisco, United States
Website
www.lyell.com

LYEL Metrics

BasicAdvanced
$317M
-
-$23.52
-0.20
-

Bulls say / Bears say

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 on April 15, 2025, which will allow more frequent discussions with regulators and recognizes its potential to address unmet needs in relapsed/refractory large B-cell lymphoma (GlobeNewswire).
As of March 31, 2025, Lyell reported cash, cash equivalents, and marketable securities totaling $330.1 million, offering sufficient capital to fund operations and reach multiple clinical milestones through 2027 (SEC 8-K).
The company remains on schedule to start the pivotal PiNACLE trial of LYL314 for third- or later-line treatment by mid-2025 and a second pivotal trial in the second-line setting by early 2026, reflecting disciplined progress of its main program (GlobeNewswire).
Lyell has received a notice from Nasdaq that it is not in compliance with the minimum bid price rule, as its shares closed below $1.00 for 33 consecutive business days. Lyell must regain compliance by July 22, 2025, or it could face delisting proceedings (TechDows).
Cash, cash equivalents, and marketable securities fell to about $297 million as of June 30, 2025, from $330.1 million on March 31, 2025, highlighting a significant cash burn rate that could limit Lyell’s financial runway to mid-2027 if not addressed (GlobeNewswire).
Lyell has discontinued its LYL119 solid tumor CAR T-cell program to focus on LYL314, which reduces pipeline diversification and raises execution risk by concentrating primarily on one lead asset (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LYEL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs